The Alzheimer's Disease Research Center at the University of California, Irvine

UCI ADRC总体 项目摘要/摘要 加州大学欧文分校阿尔茨海默病研究中心(UCI ADRC)的中心主题是 识别、量化和验证影响一生中阿尔茨海默病(AD)风险的因素。 鉴于其多样性和多因素的性质，了解其病因和进展至关重要。 包括临床和神经病理在内的多个维度的潜伏性脑功能障碍，并使用 新的科学方法，使我们能够提高知识，更好地诊断、预防和治疗 疾病。UCI ADRC在整合基础、临床和转化科学以获得 深入了解阿尔茨海默病的发病机制，并帮助实现国家阿尔茨海默氏症项目法的一些目标。 首先，我们中心在研究不同患者队列中的疾病方面有着卓越的记录：统一的数据 SET(UDS)队列，包括认知正常个体和轻度认知障碍个体 (先兆阿尔茨海默病)；患有唐氏综合症的成年人，这是阿尔茨海默病的最大遗传风险人群；以及 90，在AD病理和认知障碍之间显示出巨大的差异，是最古老的一组 个体发展成AD。总而言之，这些队列使审问与以下相关的重要新问题成为可能 年龄、易感性和韧性，使用创新成果，从体内生物标记物表征到 现代病理结果，如尸检成像和小胶质细胞染色。第二，UCI ADRC 有帮助推进该领域的创新的历史；国家第一个诱导的 作为ADRC网络的一部分的AD多能干细胞库和我们最近建立的同意- 联系招聘登记处就是这种创新的最新例子。第三，我们的中心继续发展。 鉴于UCI致力于特殊人群研究的专业知识、生产力和资源，我们有 启动了两个特殊人群核心，一个专注于唐氏综合症，另一个专注于最年长的老年人 (90)。这些核心将与ADRC的其他核心交互，以产生新的数据和资源 通过我们新成立的Biomarker Core向ADRC调查人员提供。最后，我们有 在这项提案中建立了一个新的研究和教育部分，利用了长期存在的 充满激情地致力于在UCI培训下一代临床医生和科学家。总而言之，UCI ADRC带来了充满活力和创新的多维度和多学科方法来解决 阿尔茨海默病的全国性流行。

UCI ADRC Overall Project Summary/Abstract The central theme of the University of California, Irvine Alzheimer's Disease Research Center (UCI ADRC) is to identify, quantify, and validate factors that influence the risk of Alzheimer's disease (AD) across the lifespan. Given its diverse and multifactorial nature, it is critical to understand the etiology and progression of this insidious brain disorder at multiple dimensions, including clinically and neuropathologically, and to employ novel scientific approaches so that we can advance knowledge and better diagnose, prevent and cure the disease. The UCI ADRC has a strong history of integrating basic, clinical, and translational science to gain insights into AD pathogenesis and to help meet some of the goals of the National Alzheimer's Project Act. First, our Center has a distinguished record of studying the disease in diverse patient cohorts: Uniform Data Set (UDS) Cohort, which includes cognitively normal individuals and individuals with mild cognitive impairment (prodromal AD); adults with Down syndrome, representing the largest genetically at-risk population for AD; and 90+, which show great disparity between AD pathology and cognitive loss and are among the oldest group of individuals to develop AD. Together, these cohorts enable interrogation of important novel questions related to age, susceptibility and resilience, using innovative outcomes ranging from in vivo biomarker characterization to modern pathological outcomes such as post-mortem imaging and microglial staining. Second, the UCI ADRC has a history of innovation that has helped advance the field; the development of the nation's first induced pluripotent stem cell bank for AD as part of the ADRC network and our recently established Consent-to- Contact recruitment registry are recent examples of this innovation. Third, our Center continues to evolve. Given the expertise, productivity, and resources devoted the study of special populations at UCI, we have initiated two Special Populations Cores, one focused on Down syndrome and one focused on the oldest old (90+). These Cores will interact with the other cores of the ADRC to produce novel data and resources available to ADRC investigators, including through our newly established Biomarker Core. Finally, we have established a new Research and Education Component in this proposal, which harnesses the long-standing passionate commitment to training the next generation of clinicians and scientists at UCI. In sum, the UCI ADRC brings energetic and innovative multi-dimensional and multidisciplinary approaches toward addressing the national epidemic of AD.